IP Library › Granted Patent US 12,569,452
Granted Patent B2
US 12,569,452 · App. 18/439,258 · Granted Mar 10, 2026

Ophthalmic compositions comprising F6H8

Inventors: Bernhard Günther (Dossenheim, DE); Frank Löscher (Schriesheim, DE); Hartmut Voss (Schriesheim, DE); Sonja Krösser (Heidelberg, DE); Kirsten Eickhoff (Heidelberg, DE); Daniela Willen (Oberzent, DE); Markus Beier (Weinheim, DE); Thomas Schlüter (Heidelberg, DE)
Assignee: NOVALIQ GMBH
A61K31/02A61K9/0048A61P27/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,452
App. No.
18/439,258
Granted
Mar 10, 2026
Kind
B2
Abstract

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Claims (41)

1 . A method of providing delayed ophthalmic release of a semifluorinated alkane, wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF 2 ) 6 (CH 2 ) 8 H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF 2 ) 6 (CH 2 ) 8 H, and (b) delayed release of F(CF 2 ) 6 (CH 2 ) 8 H from the enriched ophthalmic tissue;

wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;

wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease); and wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.

2 . A method of treating keratoconjunctivitis sicca (dry eye disease) due to Meibomian gland dysfunction, wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF 2 ) 6 (CH 2 ) 8 H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF 2 ) 6 (CH 2 ) 8 H, and optionally (b) delayed release of F(CF 2 ) 6 (CH 2 ) 8 H from the enriched ophthalmic tissue;

wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;

wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease); and

wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.

3 . The method according to claim 2 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 3 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

4 . The method according to claim 2 , wherein the physical methods of treating Meibomian Gland Dysfunction are selected from heat compresses, eye lid massaging, and forced expression of the Meibomian glands.

5 . The method according to claim 2 , wherein the composition is administered in a dose of a single drop per eye less than four times per day.

6 . The method according to claim 2 , wherein the composition is administered in a dose of a single drop of 10-12 μl per eye two times per day.

7 . The method of claim 2 , wherein the patient is characterized by at least 2 of the criteria selected from the group consisting of:

(i) a total ocular surface disease index (OSDI) of higher than 25;

(ii) a total corneal fluorescein staining (NEI scale) between 4 and 11;

(iii) a Schirmer's Test I greater than 5 mm; and

(iv) an MGD score of higher than 3.

8 . The method according to claim 2 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 1 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

9 . A method of treating keratoconjunctivitis sicca (dry eye disease), wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF 2 ) 6 (CH 2 ) 8 H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF 2 ) 6 (CH 2 ) 8 H, and optionally (b) delayed release of F(CF 2 ) 6 (CH 2 ) 8 H from the enriched ophthalmic tissue;

wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;

wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease); and

wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.

10 . The method according to claim 9 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 3 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

11 . The method according to claim 9 , wherein the physical methods of treating Meibomian Gland Dysfunction are selected from heat compresses, eye lid massaging, and forced expression of the Meibomian glands.

12 . The method according to claim 9 , wherein the composition is administered in a dose of a single drop per eye less than four times per day.

13 . The method according to claim 9 , wherein the composition is administered in a dose of a single drop of 10-12 μl per eye two times per day.

14 . The method of claim 9 , wherein the patient is characterized by at least 2 of the criteria selected from the group consisting of:

(i) a total ocular surface disease index (OSDI) of higher than 25;

(ii) a total corneal fluorescein staining (NEI scale) between 4 and 11;

(iii) a Schirmer's Test I greater than 5 mm; and

(iv) an MGD score of higher than 3.

15 . The method according to claim 9 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 1 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

16 . The method according to claim 1 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 1 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

17 . The method according to claim 1 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 3 wt % of 2-perfluorohexyloctane, based on the total weight of the composition.

18 . The method according to claim 1 , wherein the physical methods of treating Meibomian Gland Dysfunction are selected from heat compresses, eye lid massaging, and forced expression of the Meibomian glands.

19 . The method according to claim 1 , wherein the composition is administered in a dose of a single drop per eye less than four times per day.

20 . The method according to claim 1 , wherein the composition is administered in a dose of a single drop of 10-12 μl per eye two times per day.

21 . The method of claim 1 , wherein the patient is characterized by at least 2 of the criteria selected from the group consisting of:

(i) a total ocular surface disease index (OSDI) of higher than 25;

(ii) a total corneal fluorescein staining (NEI scale) between 4 and 11;

(iii) a Schirmer's Test I greater than 5 mm; and

(iv) an MGD score of higher than 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: GÜNTHER, BERNHARD; LÖSCHER, FRANK; VOSS, HARTMUT; KRÖSSER, SONJA; EICKHOFF, KIRSTEN; WILLEN, DANIELA; BEIER, MARKUS; SCHLÜTER, THOMAS
To: NOVALIQ GMBH
Reel/Frame 067268/0200 →
Continuity (3)
Continuation 16753701
Provisional Application 62568138 · Oct 4, 2017
Related Publication 20240245625A1 · Jul 25, 2024
References Cited (400)
US 2616927A · Kauck et al. · 1952 [cited by applicant]
US 4452818A · Haidt · 1984 [cited by applicant]
US 4649047A · Kaswan · 1987 [cited by applicant]
US 5077036A · Long · 1991 [cited by applicant]
US 5126127A · Bhagwat et al. · 1992 [cited by applicant]
US 5152997A · Ebert et al. · 1992 [cited by applicant]
US 5254338A · Sakai et al. · 1993 [cited by applicant]
US 5326566A · Parab · 1994 [cited by applicant]
US 5336175A · Mames · 1994 [cited by applicant]
US 5340567A · Cole et al. · 1994 [cited by applicant]
US 5370313A · Beard · 1994 [cited by applicant]
US 5518731A · Meadows · 1996 [cited by applicant]
US 5578020A · Mosley · 1996 [cited by applicant]
US 5667809A · Trevino et al. · 1997 [cited by applicant]
US 5849291A · Kessler · 1998 [cited by applicant]
US 5851544A · Penska et al. · 1998 [cited by applicant]
US 5874469A · Maniar et al. · 1999 [cited by applicant]
US 5874481A · Weers et al. · 1999 [cited by applicant]
US 5904933A · Riess et al. · 1999 [cited by applicant]
US 5980936A · Krafft et al. · 1999 [cited by applicant]
US 5981607A · Ding et al. · 1999 [cited by applicant]
US 6042845A · Sun et al. · 2000 [cited by applicant]
US 6060085A · Osborne · 2000 [cited by applicant]
US 6113919A · Reiss et al. · 2000 [cited by applicant]
US 6140374A · May et al. · 2000 [cited by applicant]
US 6159977A · Reeves · 2000 [cited by applicant]
US 6177477B1 · George et al. · 2001 [cited by applicant]
US 6197323B1 · Georgieff · 2001 [cited by applicant]
US 6224887B1 · Samour et al. · 2001 [cited by applicant]
US 6262105B1 · Johnstone · 2001 [cited by applicant]
US 6262126B1 · Meinert · 2001 [cited by applicant]
US 6264990B1 · Knepp et al. · 2001 [cited by applicant]
US 6294563B1 · Garst · 2001 [cited by applicant]
US 6335335B2 · Higashiyama et al. · 2002 [cited by applicant]
US 6372243B2 · Kobuch · 2002 [cited by applicant]
US 6391879B1 · Reeves · 2002 [cited by applicant]
US 6399087B1 · Zhang et al. · 2002 [cited by applicant]
US 6458376B1 · Meadows · 2002 [cited by applicant]
US 6486212B2 · Meinert · 2002 [cited by applicant]
US 6489367B1 · Meinert · 2002 [cited by applicant]
US 6528086B2 · Zhang · 2003 [cited by applicant]
US 6576663B2 · Klimko · 2003 [cited by applicant]
US 6730328B2 · Maskiewicz et al. · 2004 [cited by applicant]
US 7001607B1 · Menz et al. · 2006 [cited by applicant]
US 7026359B1 · Gross et al. · 2006 [cited by applicant]
US 7041705B2 · Mishra et al. · 2006 [cited by applicant]
US 7063241B2 · Spada et al. · 2006 [cited by applicant]
US 7074827B2 · Ueno · 2006 [cited by applicant]
US 7258869B1 · Berry et al. · 2007 [cited by applicant]
US 7283239B2 · Nonogaki et al. · 2007 [cited by applicant]
US 7335379B2 · Carrara et al. · 2008 [cited by applicant]
US 7608261B2 · Furfine et al. · 2009 [cited by applicant]
US 7687455B2 · Bonnet et al. · 2010 [cited by applicant]
US 7732415B2 · Dawson et al. · 2010 [cited by applicant]
US 7740875B2 · Dechow · 2010 [cited by applicant]
US 7776349B2 · Dechow · 2010 [cited by applicant]
US 8029977B2 · Meinert et al. · 2011 [cited by applicant]
US 8222292B2 · Goskonda et al. · 2012 [cited by applicant]
US 8309120B2 · Koch et al. · 2012 [cited by applicant]
US 8328775B2 · Gokhale et al. · 2012 [cited by applicant]
US 8338479B2 · Chang et al. · 2012 [cited by applicant]
US 8343945B2 · Tamarkin et al. · 2013 [cited by applicant]
US 8470873B2 · Chen · 2013 [cited by applicant]
US 8492334B2 · Lavik et al. · 2013 [cited by applicant]
US 8501800B2 · Bowman et al. · 2013 [cited by applicant]
US 8614178B2 · Theisinger et al. · 2013 [cited by applicant]
US 8669241B2 · Matsumura et al. · 2014 [cited by applicant]
US 8758826B2 · Bevier · 2014 [cited by applicant]
US 8759281B2 · Bonnet et al. · 2014 [cited by applicant]
US 8759404B2 · Daftary et al. · 2014 [cited by applicant]
US 8772337B2 · Pilotaz et al. · 2014 [cited by applicant]
US 8796340B2 · Theisinger et al. · 2014 [cited by applicant]
US 8865131B2 · Hagedorn et al. · 2014 [cited by applicant]
US 8916157B2 · Krause et al. · 2014 [cited by applicant]
US 8957110B2 · Aleo et al. · 2015 [cited by applicant]
US 8986738B2 · Meinert · 2015 [cited by applicant]
US 9000048B2 · Mecozzi et al. · 2015 [cited by applicant]
US 9005626B2 · Seigfried · 2015 [cited by applicant]
US 9012503B2 · Tabuchi et al. · 2015 [cited by applicant]
US 9023898B2 · Wong et al. · 2015 [cited by applicant]
US 9062275B2 · Lopez · 2015 [cited by applicant]
US 9149484B2 · Warner et al. · 2015 [cited by applicant]
US 9186305B1 · Suzuki · 2015 [cited by applicant]
US 9241900B2 · Wilson · 2016 [cited by applicant]
US 9265809B2 · Johnson · 2016 [cited by applicant]
US 9278120B2 · Cruzat et al. · 2016 [cited by applicant]
US 9308262B2 · Günther et al. · 2016 [cited by applicant]
US 9446026B2 · Bingaman et al. · 2016 [cited by applicant]
US 9549906B2 · Lynch et al. · 2017 [cited by applicant]
US 9630941B2 · Elsohly et al. · 2017 [cited by applicant]
US 9757459B2 · Günther et al. · 2017 [cited by applicant]
US 9757460B2 · Günther et al. · 2017 [cited by applicant]
US 9770508B2 · Günther et al. · 2017 [cited by applicant]
US 9814695B2 · Anastassov et al. · 2017 [cited by applicant]
US 9844530B1 · Anastassov et al. · 2017 [cited by applicant]
US 9878000B2 · Gu et al. · 2018 [cited by applicant]
US 9968678B2 · Theisinger et al. · 2018 [cited by applicant]
US 9982032B2 · Park et al. · 2018 [cited by applicant]
US 10004714B2 · Zhu et al. · 2018 [cited by applicant]
US 10045996B2 · Theisinger et al. · 2018 [cited by applicant]
US 10045997B2 · Chen et al. · 2018 [cited by applicant]
US 10058615B2 · Günther et al. · 2018 [cited by applicant]
US 10064944B2 · Wilson · 2018 [cited by applicant]
US 10123904B2 · Chauhan et al. · 2018 [cited by applicant]
US 10130707B2 · Günther et al. · 2018 [cited by applicant]
US 10273298B2 · Günther et al. · 2019 [cited by applicant]
US 10286035B2 · Gavaris · 2019 [cited by applicant]
US 10369117B2 · Günther et al. · 2019 [cited by applicant]
US 10449164B2 · Günther et al. · 2019 [cited by applicant]
US 10507132B2 · Graf et al. · 2019 [cited by applicant]
US 10525062B2 · Theisinger et al. · 2020 [cited by applicant]
US 10543121B2 · Labombarbe et al. · 2020 [cited by applicant]
US 10555953B2 · Theisinger et al. · 2020 [cited by applicant]
US 10576154B2 · Günther et al. · 2020 [cited by applicant]
US 10668010B2 · Ficko · 2020 [cited by applicant]
US 10682315B2 · Scherer et al. · 2020 [cited by applicant]
US 10813976B2 · Loscher et al. · 2020 [cited by applicant]
US 10813999B2 · Günther et al. · 2020 [cited by applicant]
US 10925927B2 · Brockmeyer et al. · 2021 [cited by applicant]
US 11135266B2 · Kerwin et al. · 2021 [cited by applicant]
US 11154513B2 · Scherer et al. · 2021 [cited by applicant]
US 11160865B2 · Theisinger et al. · 2021 [cited by applicant]
US 11241497B2 · Reza et al. · 2022 [cited by applicant]
US 11273174B2 · Löscher et al. · 2022 [cited by applicant]
US 11278503B2 · Günther et al. · 2022 [cited by applicant]
US 11285163B2 · Shah et al. · 2022 [cited by applicant]
US 11324757B2 · Theisinger et al. · 2022 [cited by applicant]
US 11357738B2 · Scherer et al. · 2022 [cited by applicant]
US 11400132B2 · Löscher et al. · 2022 [cited by applicant]
US 11413323B2 · Leo et al. · 2022 [cited by applicant]
US 11457626B2 · Dyer · 2022 [cited by applicant]
US 11576893B2 · Löscher et al. · 2023 [cited by applicant]
US 11583513B2 · Günther et al. · 2023 [cited by applicant]
US 11684589B2 · Günther et al. · 2023 [cited by applicant]
US 11723861B2 · Günther et al. · 2023 [cited by applicant]
US 11730794B2 · Yancopoulos · 2023 [cited by applicant]
US 11844836B2 · Günther et al. · 2023 [cited by applicant]
US 11896559B2 · Günther et al. · 2024 [cited by applicant]
US 11987623B2 · Günther et al. · 2024 [cited by applicant]
US 12005033B2 · Günther et al. · 2024 [cited by applicant]
US RE50060E · Graf et al. · 2024 [cited by applicant]
US 12029757B2 · Löscher et al. · 2024 [cited by applicant]
US 12059449B2 · Leo et al. · 2024 [cited by applicant]
US 12128010B2 · Scherer et al. · 2024 [cited by applicant]
US 12150955B2 · Löscher et al. · 2024 [cited by applicant]
US 12226422B2 · Löscher et al. · 2025 [cited by applicant]
US 20020004063A1 · Zhang · 2002 [cited by applicant]
US 20020006442A1 · Mishra et al. · 2002 [cited by applicant]
US 20020128527A1 · Meinert · 2002 [cited by applicant]
US 20020137793A1 · Klimko · 2002 [cited by applicant]
US 20030018044A1 · Peymar · 2003 [cited by applicant]
US 20030027833A1 · Cleary et al. · 2003 [cited by applicant]
US 20030170194A1 · Piotrowiak · 2003 [cited by applicant]
US 20040044045A1 · Burk · 2004 [cited by applicant]
US 20040082660A1 · Ueno · 2004 [cited by applicant]
US 20040101551A1 · Selzer · 2004 [cited by applicant]
US 20040265362A1 · Susilo · 2004 [cited by applicant]
US 20040266702A1 · Dawson et al. · 2004 [cited by applicant]
US 20050075407A1 · Tamarkin et al. · 2005 [cited by applicant]
US 20050079210A1 · Gupta · 2005 [cited by applicant]
US 20050084553A1 · Moon et al. · 2005 [cited by applicant]
US 20050175541A1 · Lanza et al. · 2005 [cited by applicant]
US 20050274744A1 · Spada et al. · 2005 [cited by applicant]
US 20050288196A1 · Horn · 2005 [cited by applicant]
US 20060009522A1 · Reza et al. · 2006 [cited by applicant]
US 20060078580A1 · Dechow · 2006 [cited by applicant]
US 20060153905A1 · Carrara et al. · 2006 [cited by applicant]
US 20070238732A1 · Graham et al. · 2007 [cited by applicant]
US 20080019926A1 · Krafft et al. · 2008 [cited by applicant]
US 20080039807A1 · Pine · 2008 [cited by applicant]
US 20080050335A1 · Faour et al. · 2008 [cited by applicant]
US 20080089923A1 · Burkstrand et al. · 2008 [cited by applicant]
US 20080112895A1 · Kottayil et al. · 2008 [cited by applicant]
US 20080153909A1 · Dana et al. · 2008 [cited by applicant]
US 20080207537A1 · Turner et al. · 2008 [cited by applicant]
US 20080234389A1 · Mecozzi et al. · 2008 [cited by applicant]
US 20080254106A1 · Bell · 2008 [cited by applicant]
US 20080260656A1 · Mallard · 2008 [cited by applicant]
US 20090136430A1 · Dugger · 2009 [cited by applicant]
US 20090149546A1 · Chang et al. · 2009 [cited by applicant]
US 20090169601A1 · Koch et al. · 2009 [cited by applicant]
US 20100006600A1 · Dascanio · 2010 [cited by applicant]
US 20100008996A1 · Meinert · 2010 [cited by applicant]
US 20100016814A1 · Gokhale et al. · 2010 [cited by applicant]
US 20100137252A1 · Matsumura et al. · 2010 [cited by applicant]
US 20100189765A1 · Erickson et al. · 2010 [cited by applicant]
US 20100226997A1 · Bowman et al. · 2010 [cited by applicant]
US 20100274215A1 · Wong et al. · 2010 [cited by applicant]
US 20100310476A1 · Tamarkin et al. · 2010 [cited by applicant]
US 20110223208A1 · Hill et al. · 2011 [cited by applicant]
US 20110269704A1 · Seigfried · 2011 [cited by applicant]
US 20120010280A1 · Aleo et al. · 2012 [cited by applicant]
US 20120053242A1 · Cela Lopez · 2012 [cited by applicant]
US 20120095097A1 · Tabuchi et al. · 2012 [cited by applicant]
US 20120100183A1 · Schlessinger et al. · 2012 [cited by applicant]
US 20120219640A1 · Wright · 2012 [cited by applicant]
US 20120238639A1 · Theisinger et al. · 2012 [cited by applicant]
US 20120244177A1 · Theisinger et al. · 2012 [cited by applicant]
US 20130011484A1 · Bevier · 2013 [cited by applicant]
US 20130046014A1 · Theisinger et al. · 2013 [cited by applicant]
US 20130084250A1 · Hagedorn et al. · 2013 [cited by applicant]
US 20130266652A1 · Theisinger et al. · 2013 [cited by applicant]
US 20130303473A1 · Wilson · 2013 [cited by applicant]
US 20130309226A1 · Armstrong et al. · 2013 [cited by applicant]
US 20130336557A1 · Cruzat et al. · 2013 [cited by applicant]
US 20140004197A1 · Theisinger et al. · 2014 [cited by applicant]
US 20140100180A1 · Günther et al. · 2014 [cited by applicant]
US 20140140942A1 · Günther et al. · 2014 [cited by applicant]
US 20140186350A1 · Ghosh et al. · 2014 [cited by applicant]
US 20140303219A1 · Bingaman et al. · 2014 [cited by applicant]
US 20140369993A1 · Günther et al. · 2014 [cited by applicant]
US 20150045282A1 · Elsohly et al. · 2015 [cited by applicant]
US 20150099019A1 · Johnson · 2015 [cited by applicant]
US 20150174096A1 · Bottger et al. · 2015 [cited by applicant]
US 20150224064A1 · Günther et al. · 2015 [cited by applicant]
US 20150238605A1 · Günther et al. · 2015 [cited by applicant]
US 20150258040A1 · Lynch et al. · 2015 [cited by applicant]
US 20160000941A1 · Keller et al. · 2016 [cited by applicant]
US 20160101178A1 · Wilson · 2016 [cited by applicant]
US 20160159902A1 · Günther et al. · 2016 [cited by applicant]
US 20160184259A1 · Anastassov et al. · 2016 [cited by applicant]
US 20160243189A1 · Gu et al. · 2016 [cited by applicant]
US 20160303031A1 · El Achkar et al. · 2016 [cited by applicant]
US 20170020726A1 · Labombarbe et al. · 2017 [cited by applicant]
US 20170087100A1 · Scherer et al. · 2017 [cited by applicant]
US 20170087101A1 · Scherer et al. · 2017 [cited by applicant]
US 20170182060A1 · Wiedersberg et al. · 2017 [cited by applicant]
US 20170216204A1 · Theisinger et al. · 2017 [cited by applicant]
US 20170348285A1 · Hellstrom · 2017 [cited by applicant]
US 20180360908A1 · Beier et al. · 2018 [cited by applicant]
US 20190256591A1 · Günther et al. · 2019 [cited by applicant]
US 20190274970A1 · Günther et al. · 2019 [cited by applicant]
US 20190328717A1 · Günther et al. · 2019 [cited by applicant]
US 20190343793A1 · Günther et al. · 2019 [cited by applicant]
US 20200060987A1 · Günther et al. · 2020 [cited by applicant]
US 20200188318A1 · Günther et al. · 2020 [cited by applicant]
US 20200206241A1 · Theisinger et al. · 2020 [cited by applicant]
US 20200246463A1 · Günther et al. · 2020 [cited by applicant]
US 20200338015A1 · Scherer et al. · 2020 [cited by applicant]
US 20210069014A1 · Löscher et al. · 2021 [cited by applicant]
US 20210121471A1 · Löscher et al. · 2021 [cited by applicant]
US 20210228595A1 · Löscher et al. · 2021 [cited by applicant]
US 20210236591A1 · Leo et al. · 2021 [cited by applicant]
US 20210315832A1 · Scherer et al. · 2021 [cited by applicant]
US 20210340248A1 · Günther et al. · 2021 [cited by applicant]
US 20210346313A1 · Beier et al. · 2021 [cited by applicant]
US 20220008397A1 · Xu et al. · 2022 [cited by applicant]
US 20220031844A1 · Mauden et al. · 2022 [cited by applicant]
US 20220079925A1 · Günther et al. · 2022 [cited by applicant]
US 20220143137A1 · Witt et al. · 2022 [cited by applicant]
US 20220152096A1 · Löscher et al. · 2022 [cited by applicant]
US 20220226426A1 · Löscher et al. · 2022 [cited by applicant]
US 20220226427A1 · Leo et al. · 2022 [cited by applicant]
US 20220354786A1 · Friess et al. · 2022 [cited by applicant]
US 20220354926A1 · Löscher et al. · 2022 [cited by applicant]
US 20220362382A1 · Löscher et al. · 2022 [cited by applicant]
US 20220370377A1 · Scherer et al. · 2022 [cited by applicant]
US 20230043641A1 · Beier et al. · 2023 [cited by applicant]
US 20230139672A1 · Theisinger et al. · 2023 [cited by applicant]
US 20230181679A1 · Haisser et al. · 2023 [cited by applicant]
US 20230330056A1 · Günther et al. · 2023 [cited by applicant]
US 20230398065A1 · Günther et al. · 2023 [cited by applicant]
CA 3021394 · 2021 [cited by applicant]
CN 200977281Y · 2007 [cited by applicant]
CN 202136470U · 2012 [cited by applicant]
CN 203524843U · 2014 [cited by applicant]
EP 0089815A1 · 1983 [cited by applicant]
EP 0593552A1 · 1994 [cited by applicant]
EP 0670159A1 · 1995 [cited by applicant]
EP 0965329A1 · 1999 [cited by applicant]
EP 0965334A1 · 1999 [cited by applicant]
EP 0939655A1 · 2002 [cited by applicant]
EP 1152749A2 · 2006 [cited by applicant]
EP 2110126A1 · 2009 [cited by applicant]
EP 2332525A1 · 2011 [cited by applicant]
EP 2335735A1 · 2011 [cited by applicant]
EP 2462921A1 · 2012 [cited by applicant]
EP 2708228A1 · 2014 [cited by applicant]
EP 2730291A1 · 2014 [cited by applicant]
JP S6452722A · 1989 [cited by applicant]
JP H0764702B2 · 1995 [cited by applicant]
JP 2000511157A · 2000 [cited by applicant]
JP 2001158734A · 2001 [cited by applicant]
JP 2008505177A · 2008 [cited by applicant]
JP 2011006348A · 2011 [cited by applicant]
JP 2011024841A · 2011 [cited by applicant]
WO WO93000991A1 · 1993 [cited by applicant]
WO WO95033447A1 · 1995 [cited by applicant]
WO WO96040052A1 · 1996 [cited by applicant]
WO WO97012852A1 · 1997 [cited by applicant]
WO WO98005301A1 · 1998 [cited by applicant]
WO WO00010531A1 · 2000 [cited by applicant]
WO WO00024376A1 · 2000 [cited by applicant]
WO WO00054588A1 · 2000 [cited by applicant]
WO WO2002049631 · 2002 [cited by applicant]
WO WO2003099258 · 2003 [cited by applicant]
WO WO2005018530 · 2005 [cited by applicant]
WO WO2005099718 · 2005 [cited by applicant]
WO WO2005099752 · 2005 [cited by applicant]
WO WO2005123035 · 2005 [cited by applicant]
WO WO2006007510 · 2006 [cited by applicant]
WO WO2006042059 · 2006 [cited by applicant]
WO WO2006048242 · 2006 [cited by applicant]
WO WO2007008666 · 2007 [cited by applicant]
WO WO2007052288 · 2007 [cited by applicant]
WO WO2008060359 · 2008 [cited by applicant]
WO WO2009013435 · 2009 [cited by applicant]
WO WO2009065565 · 2009 [cited by applicant]
WO WO2010062394 · 2010 [cited by applicant]
WO WO2010146536 · 2010 [cited by applicant]
WO WO2011009436 · 2011 [cited by applicant]
WO WO2011073134 · 2011 [cited by applicant]
WO WO2011113855 · 2011 [cited by applicant]
WO WO2011151079 · 2011 [cited by applicant]
WO WO2012052418 · 2012 [cited by applicant]
WO WO2012062834 · 2012 [cited by applicant]
WO WO2012093113 · 2012 [cited by applicant]
WO WO2012121754 · 2012 [cited by applicant]
WO WO2012160179 · 2012 [cited by applicant]
WO WO2012160180 · 2012 [cited by applicant]
WO WO2013110621 · 2013 [cited by applicant]
WO WO2014041055 · 2014 [cited by applicant]
WO WO2014041071 · 2014 [cited by applicant]
WO WO2014154531 · 2014 [cited by applicant]
WO WO2015011199 · 2015 [cited by applicant]
WO WO2016025560 · 2016 [cited by applicant]
WO WO2016082644A1 · 2016 [cited by applicant]
WO WO2017055453 · 2017 [cited by applicant]
WO WO2017220625 · 2017 [cited by applicant]
WO WO2018060282 · 2018 [cited by applicant]
WO WO2018114557 · 2018 [cited by applicant]
WO WO2018115097 · 2018 [cited by applicant]
WO 2020074697A1 · 2020 [cited by applicant]
“EvoTears, Product Description” Accessed Online: Dec. 21, 2023. https://evotears.com/at/das-produkt/ (Year: 2017). [cited by applicant]
“Ocular Surface Disease Index (OSDI)”, Dec. 1, 2003, pp. 1-2, Retrieved from the Internet: URL: http://www.supereyecare.com/resources/OSDI.pdf. [cited by applicant]
“Topical drug dosage forms for eye conditions,” The Pharmaceutical Journal, (Pharmaceutical Press, May 31, 2017), available at https://pharmaceutical-journal.com/article/ld/topical-drug-dosage-forms-for-eye-conditions. [cited by applicant]
“Xerophthalmia,” Eye Clinic, 4 pages, archived Dec. 30, 2014. [cited by applicant]
Agarwal et al., “Modern Approaches to the Ocular Delivery of Cyclosporine A,” Drug Discovery Today, vol. 21, No. 6, pp. 977-988, (2016); doi: 10.1016/j.drudis.2016.04.002. [cited by applicant]
Ahmed, S. et al., “Ocular Drug Delivery: a Comprehensive Review,” AAPS PharmSciTech, vol. 24, No. 66, pp. 1-29, (2023). [cited by applicant]
Ann Marie Griff, O.D., & Ann Pietrangelo, “Everything you need to know about keratoconjunctivitis,” Healthline.com, Nov. 22, 2019, downloaded from https://www.healthline.com/health/keratoconjunctivitis. [cited by applicant]
Benezra, D. et al., “Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis,” American Journal of Ophthalmology, vol. 101, pp. 278-282, (1986). [cited by applicant]
Bron, A. et al., “Grading of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests,” Cornea, vol. 22, No. 7, pp. 640-650, (2003). [cited by applicant]
Dutescu, R. et al., “Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, No. 1, pp. 123-128, (2014). [cited by applicant]
Eva M. del Amo, “Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?” Frontiers in Drug Discovery 2:954771 (Sep. 8, 2022), available at https://www.fro… [cited by applicant]
Günther, B., “Breaking the Vicious Circle of Dry Eye Disease,” OIS@ SECO, Feb. 21, 2019, pp. 1-14, New Orleans, URL: https://ois.net/wp-content/uploads/2019/02/DryEye-Novaliq.pdf. [cited by applicant]
Keratoconjunctivitis, Cleveland Clinic, last updated Jul. 8, 2022, downloaded from https://my.clevelandclinic.org/health/diseases/23551-keratoconjunctivitis. [cited by applicant]
Kumar, S. et al., “Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment,” J. Adv. Pharm. Tech. Res., vol. 2, No. 3, (2011). [cited by applicant]
Li, Y. et al., “Limited Scleroderma (Crest Syndrome) is Associated with Worse Xerostomia and Xerophthalmia in Patients Being Evaluated for Primary Sjogren's Syndrome,” Scientific Abstracts; FRI0432, pp. 583-584, (2015). [cited by applicant]
Miller, K. et al., “Minimal Clinically Important Difference for the Ocular Surface Disease Index,” Socioeconomics and Health Services, Arch Ophthalmol, vol. 128, No. 1, pp. 94-101, (2010). [cited by applicant]
Moscovici, B. et al., “Clinical treatment of dry eye using 0.03% tacrolimus eye drops,” Cornea, vol. 31, No. 8, pp. 945-949, (2012). [cited by applicant]
Murphy, C. et al., “Cyclosporine vs Tacrolimus Therapy for Posterior and Intermediate Uveitis,” Arch Ophthalmol., vol. 123, pp. 634-641, (2005). [cited by applicant]
Qiao, J. et al., “Emerging treatment options for meibomian gland dysfunction,” Clinical Ophthalmology, vol. 7, pp. 1797-1803, (2013). [cited by applicant]
RESTASIS® Prescribing Information, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf (Nov. 2012) (last accessed Feb. 28, 2023). [cited by applicant]
Sheppard, J. et al., “A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study,” Cornea, vol. 40, No. 10, pp. 1290-1297, (2021). [cited by applicant]
Steven, P. et al., “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study,” Investigative Ophthalmology & Visual Science, vol. 56, p. 4493, (2015), Abstract… [cited by applicant]
Torkildsen, G. et al., “A Clinical Phase 2 Study to Assess Safety, Efficacy, and Tolerability of CyclASol for the Treatment of Dry Eye Disease,” Poster Presentation at American Academy of Ophthalmology (AAO), New Orlean… [cited by applicant]
Agarwal, P. et al., “Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs,” International Journal of Pharmaceutics, vol. 538, No. 1-2, pp. 119-129, (2018). [cited by applicant]
Ganka, A., “Definition and Diagnostic Criteria for Meibomian Gland Dysfunction,” Journal of Ophthalmology, vol. 27, No. 5, pp. 627-631, 6 pages, (2010), abstract only. [cited by applicant]
Pensyl, D., “Chapter 14: Preparations for Dry Eye and Ocular Surface Disease,” Clinical Ocular Pharmacology, Fifth Edition, pp. 263-278, 18 pages, (2008). [cited by applicant]
Santvliet, L. et al., “Determinants of Eye Drop Size,” Survey of Ophthalmology, vol. 49, No. 2, pp. 197-213, (2004). [cited by applicant]
Schmitt, M., “Chapter 10: Design and Development of Ocular Formulations for Preclinical and Clinical Trials,” Innovative Dosage Forms: Design and Development at Early Stage, pp. 331-365, 35 pages, (2020). [cited by applicant]
Zeev, M. et al., “Diagnosis of dry eye disease and emerging technologies,” Clinical Ophthalmology, vol. 8, pp. 581-590, 11 pages, (2014). [cited by applicant]
“Novaliq GmbH Begins Phase II Clinical Trial of Cyclasol for the Treatment of Moderate to Severe Dry Eye Disease,” (online), 5 pages, (2016); retrieved on Jan. 8, 2021 from the Internet: https://www.biospace.com/article… [cited by applicant]
“What is retinal vitrectomy?”, Presented by: Medical Online, Obesity and Diabetes Mellitus, vol. 4, No. 2, pp. 284-286, (2005). [cited by applicant]
“EvoTears—Gebrauchsanweisung,” May 2015, retrieved from the Internet, date retrieved: Jun. 26, 2018, 2 pages, URL: http://video.apo-rot.de/docs/11213615.pdf. [cited by applicant]
“Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol® in Adults with Moderate to Severe Dry Eye Disease,” Businesswire, Jan. 5, 2017, URL: <https://www.businesswire.com/news/home/201… [cited by applicant]
“Novaliq begins Phase 2 trial of Cyclasol for dry eye disease,” Optometry Times, vol. 8, No. 3, (2016), p. 24. [cited by applicant]
“Semifluorinated alkane technology brings advantages for topical therapy,” Ophthalmology Times, 2016, pp. 1-2. [cited by applicant]
Agrahari, et al., “A comprehensive insight on ocular pharmacokinetics,” Drug Delivery and Translational Research, vol. 6, No. 6, pp. 735-754, (2016). [cited by applicant]
Ahmed, I. et al., “Disposition of Timolol and Inulin in the Rabbit Eye Following Corneal Versus Non-Corneal Absorption,” International Journal of Pharmaceutics, vol. 38, pp. 9-21, (1987). [cited by applicant]
Baerdemaeker, L. et al., “Pharmacokinetics in Obese Patients,” Continuing Education in Anaesthesia, Critical Care & Pain, vol. 4, pp. 152-155, (2004). [cited by applicant]
Bardin et al., “Long-Range Nanometer-Scale Organization of Semifluorinated Alkane Monolayers at the Air/Water Interface,” Langmuir, vol. 27, pp. 13497-13505, (2011). [cited by applicant]
Bertilla et al., “Semifluorinated Alkanes as Stabilizing Agents of Fluorocarbon Emulsions,” Springer, vol. 12, 24 pages, (2005). [cited by applicant]
Blackie et al., “Getting to the Root Cause of Dry Eye”, Review of Optometry, pp. 1-12, (2012). [cited by applicant]
Broniatowski, M. et al., “Langmuir Monolayers Characteristic of (Perfluorodecyl)-Alkanes,” Journal of Physical Chemistry B, vol. 108, pp. 13403-13411, (2004). [cited by applicant]
Chao, W. et al., “Report of the Inaugural Meeting of the TFOS i2 = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment,” (London, United Kingdom, Mar. 21, 2015) Accepted Manuscript, Accepted Dat… [cited by applicant]
Chemical Book, 5-Fluorouracil, available at <http://www.chemicalbook.com/ChemicalProductProperty_EN_CB8162744.htm>, 1 page, accessed Mar. 7, 2014. [cited by applicant]
Chhadva et al., “Meibomian Gland Disease The Role of Gland Dysfunction in Drye Eye Disease,” Ophthalmology, vol. 124, No. 11 Supplement, pp. S20-S26, (2017). [cited by applicant]
Costa Gomes et al., “Solubility of dioxygen in seven fluorinated liquids,” Journal of Fluorine Chemistry, vol. 125, pp. 1325-1329, (2004). [cited by applicant]
Davies, N., “Biopharmaceutical Considerations in Topical Ocular Drug Delivery,” Clinical and Experimental Pharmacology and Physiology, vol. 27, pp. 558-562, (2000). [cited by applicant]
Dembinski, R. et al., “Semi-fluorinated Alkanes as Carriers for Drug Targeting in Acute Respiratory Failure,” Experimental Lung Research, vol. 36, pp. 499-507, (2010). [cited by applicant]
Deschamps, J. et al., “Solubility of oxygen, carbon dioxide and water in semifluorinated alkanes and in perfluorooctylbromide by molecular simulation”, Journal of Fluorine Chemistry, Elsevier, vol. 125, No. 3, (2004). [cited by applicant]
Dias et al., “Solubility of oxygen in liquid perfluorocarbons,” Fluid Phase Equilibria, vol. 222-223, pp. 325-330, (2004). [cited by applicant]
Dutescu et al., “Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, No. 1, pp. 123-128, (2014), (Abstract Only). [cited by applicant]
Elkeeb, R. et al., “Transungual Drug Delivery: Current Status,” International Journal of Pharmaceutics, vol. 384, pp. 1-8, (2010). [cited by applicant]
English-language machine translation of EP0670159 (A1) issued in U.S. Appl. No. 14/122,025 on Apr. 1, 2015, 10 pages. [cited by applicant]
Freiburger Dokumentenserver (FreiDok), Albert-Ludwigs-Unversität Freiburg, retrieved from http://www.freidok.uni-freiburg.de/volltexte/5682/, retrieved on Feb. 5, 2014, 2 pages. [cited by applicant]
Gayton, J., “Etiology, Prevalence, and Treatment of Dry Eye Disease,” Clinical Ophthalmology, vol. 3, pp. 405-412, (2009). [cited by applicant]
Gehlsen et al., “A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye,” Graefe's Arch. Clin. Exp. Ophthalmol., vol. 255, N… [cited by applicant]
Gehlsen, U., et al., “Omega-3 Fatty Acids Using F6H8-Carrier as Topical Therapy in Experimental Dry-Eye Disease,” Investigative Ophthalmology & Visual Science, vol. 57, pp. 417, (2016), (Abstract Only). [cited by applicant]
Gehlsen. U., et al., “Cyclosporine A using F4H5 as liquid drug carrier is effective in treating experimental dry-eye disease,” Investigative Ophthalmology & Visual Science, vol. 56, No. 319, (2015), (Abstract Only). [cited by applicant]
Gerdenitsch, “Emulsions—established and promising drug carriers for parenteral adminstration”, retrieved from internet: http:/ipimediaworld.com/wp- content/uploads/2012/05/Pages-from-IPI-Volume-2-Issue- I - I I .pdf. Da… [cited by applicant]
German, E.J., et al., “Reality of drop size from multi-dose eye drop bottles: is it cause for concern?” Eye, vol. 13, pp. 93-100, (1999). [cited by applicant]
Griffin, W., “Classification of Surface-Active Agents by ‘HLB’,” Journal of the Society of Cosmetic Chemists, vol. 1, pp. 311-326, (1949). [cited by applicant]
Hardung, H., “Semifluorierte und perfluorierte Verbindungen zur topischen und parenteralen Anwendung,” 2008, English Language Abstract, 2 pages, retrieved from https://freidok.uni-freiburg.de/data/5682 (retrieved on Jul… [cited by applicant]
Hardung, H., “Semifluorierte und perfluorierte Verbindungen zur topischen und parenteralen Anwendung,” 2008, retrieved from http://www.freidok.uni-freiburg.de/volltexte/5682/pdf/Dissertation_Hardung.pdf (retrieved on Oc… [cited by applicant]
Hoerauf, H. et al., “Combined Use of Partially Fluorinated Alkanes, Perfluorocarbon Liquids and Silicone Oil: An Experimental Study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 239, No. 5, pp. 37… [cited by applicant]
Holm, R. et al., “A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs,” European Journal of Pharmaceutical Sciences, vol. 42, pp. 416-422, (2011). [cited by applicant]
International Preliminary Report on Patentability dated Apr. 2, 2019, for International Application No. PCT/EP2017/074545, 7 pages. [cited by applicant]
International Preliminary Report on Patentability dated Dec. 25, 2018, for International Application No. PCT/EP2017/065163, 6 pages. [cited by applicant]